Loading clinical trials...

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India | Clinical Trials | Clareo Health

COMPLETEDPHASE4

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India

A 24-week Multicenter, Open-label, Single-arm Study to Evaluate Safety in Patients With Type 2 Diabetes Mellitus in India Treated With Dulaglutide

NCT05659537•Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The main purpose of this study is to evaluate safety of dulaglutide in participants with type 2 diabetes mellitus in India.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Have a diagnosis of type 2 diabetes mellitus (T2DM) of at least 1-year duration currently treated with stable doses of oral antihyperglycemic medications with or without stable doses of basal or premix insulin for the last 3 months prior to screening
•Have hemoglobin A1c (HbA1c) greater than or equal to (≥) 7.5 percent (%) and less than or equal to (≤) 11.5%, both inclusive, at screening
•Have body mass index (BMI) ≥ 23 kilogram/square meter (kg/m²)

Exclusion Criteria

•A diagnosis of type 1 diabetes mellitus (T1DM) or latent autoimmune diabetes, or specific type of diabetes other than T2DM
•Been treated with antihyperglycemic medication like glucagon-like peptide receptor agonists (GLP-1 RA) or have a prior history of any contraindication to GLP-1 RA therapy within 3 months prior to screening or estimated glomerular filtration rate (eGFR) \<15 milliliter/minute (ml/min)/1.73 square meter (m²)
•Participants have known hypersensitivity or allergy to dulaglutide or its excipients
•Participants are on systemic steroids for any period of more than 14 days
•Participants have severe gastrointestinal (GI) disease, including severe gastroparesis
•Participants have an active or untreated malignancy, except for successfully treated basal or squamous cell carcinoma

Locations (7)

Medlink Hospital Opp Someshwara Jain Temple

Ahmedabad, Ambavadi, India

Life Care Hospital and Research Centre

Bangalore, Karnataka, India

Grant Medical Foundation - Ruby Hall Clinic

Pune, Maharashtra, India

Akshay Hospital

Pune, Maharashtra, India

Lifepoint Multispecialty Hsptl

Wakad, Pune, India

Kovai Diabetes Speciality Center and Hospital

Coimbatore, Tamil Nadu, India

Virinchi Hospital

Hyderabad, Telangana, India

Key Dates

Start Date

December 29, 2022

Primary Completion Date

January 16, 2024

Completion Date

January 16, 2024

Last Updated

February 20, 2025

Enrollment

212

ACTUAL participants

Conditions

Diabetes Mellitus, Type 2

Interventions

Dulaglutide

DRUG

PATHS-UP Health Behavior Self-monitoring Mobile App for Adolescents

NCT06959901

Obesity and Diabetes Mellitus, Type 2Diabetes Prevention

View study

RECRUITINGNA

Michigan Men's Diabetes Project III(MenDIII): Mind and Motion

NCT06574035

Diabetes Mellitus, Type 2Depressive Symptoms+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 20, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India

Inclusion Criteria

Exclusion Criteria

PATHS-UP Health Behavior Self-monitoring Mobile App for Adolescents

Michigan Men's Diabetes Project III(MenDIII): Mind and Motion

Effects of Vitamin D3 and Yeast Beta-Glucan Supplementation on Glycemic Control and Cardiovascular Disease Risk in Patients With Type 2 Diabetes

Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use

Prediction of Heart Failure and Cognitive Decline in Type 2 Diabetes

Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH)